
VYGR • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold VYGR in your mock portfolio yet.
Voyager Therapeutics is currently unprofitable, as indicated by its negative EPS and PE ratio. The figures suggest ongoing losses with no clear evidence of near-term profitability from the data provided. This positions the stock more as a speculative, development-stage biotech play rather than a cash-generating business.
The stock trades at $4.08, modestly above its 200-day moving average of $3.76, suggesting a slightly positive longer-term trend despite minimal movement over the last month. An RSI of 42.60 indicates neither overbought nor oversold conditions, implying a lack of strong momentum in either direction. Overall, the technical picture is balanced with a slight upward bias but no clear breakout signal.
Alternative data for Voyager Therapeutics shows stability rather than strong growth or deterioration. Website traffic and job postings are flat, while LinkedIn followers are growing modestly and Twitter/X is stagnant. These signals point to steady but not rapidly accelerating interest or expansion.
Voyager Therapeutics presents a mixed picture: financially it remains loss-making, but its stock is trading modestly above its long-term average and alternative data show stable interest. The setup looks like a typical development-stage biotech—highly dependent on future catalysts rather than current fundamentals. Overall, the balance of weak profitability and neutral-to-slightly-positive technical and alternative signals supports a neutral stance.


Genflow is ready for “a year of catalysts” - ICYMI


Voyager Reports Third Quarter 2025 Financial and Operating Results
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: